Zura Bio: Phase 2 TibuSHIELD misses primary endpoint, discontinues HS development
FROM THE WIRE · FINANCE.YAHOO.COM
Study did not meet primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN) count at Week 16 Key secondary endpoints, including HiSCR50 and HiSCR75, were not met Both doses of tibulizumab were well tolerated; observed safety was…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe failed key study and HS discontinuation reduce the value of the tibulizumab pipeline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The study missed its primary endpoint and key secondary endpoints HiSCR50 and HiSCR75.
- 02Both doses were well tolerated, with a safety profile consistent with prior data.
- 03TibuSURE in systemic sclerosis and NEXUS-PMR in polymyalgia rheumatica will continue.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets